These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36755352)

  • 1. Complement-targeted therapeutics: An emerging field enabled by academic drug discovery.
    Lamers C; Ricklin D; Lambris JD
    Am J Hematol; 2023 May; 98 Suppl 4():S82-S89. PubMed ID: 36755352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement-targeted therapeutics.
    Ricklin D; Lambris JD
    Nat Biotechnol; 2007 Nov; 25(11):1265-75. PubMed ID: 17989689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical promise of next-generation complement therapeutics.
    Mastellos DC; Ricklin D; Lambris JD
    Nat Rev Drug Discov; 2019 Sep; 18(9):707-729. PubMed ID: 31324874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renaissance of complement therapeutics.
    Ricklin D; Mastellos DC; Reis ES; Lambris JD
    Nat Rev Nephrol; 2018 Jan; 14(1):26-47. PubMed ID: 29199277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.
    Mastellos DC; Reis ES; Yancopoulou D; Hajishengallis G; Ricklin D; Lambris JD
    Immunobiology; 2016 Oct; 221(10):1046-57. PubMed ID: 27353192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New milestones ahead in complement-targeted therapy.
    Ricklin D; Lambris JD
    Semin Immunol; 2016 Jun; 28(3):208-22. PubMed ID: 27321574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-targeted complement therapeutics.
    Tomlinson S; Thurman JM
    Mol Immunol; 2018 Oct; 102():120-128. PubMed ID: 30220307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulators of complement activation: a patent review (2008 - 2013).
    Larghi EL; Kaufman TS
    Expert Opin Ther Pat; 2014 Jun; 24(6):665-86. PubMed ID: 24640971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New Complement Therapeutics in Complement-Related Diseases].
    Wakamiya N; Ohtani K; Hidaka Y; Inoue N
    Brain Nerve; 2019 Jun; 71(6):555-564. PubMed ID: 31171752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement: A primer for the coming therapeutic revolution.
    Barnum SR
    Pharmacol Ther; 2017 Apr; 172():63-72. PubMed ID: 27914981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease.
    de Boer ECW; van Mourik AG; Jongerius I
    Front Immunol; 2020; 11():578069. PubMed ID: 33362763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond.
    Gavriilaki E; de Latour RP; Risitano AM
    Blood; 2022 Jun; 139(25):3571-3582. PubMed ID: 34482398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding horizons in complement drug discovery: challenges and emerging strategies.
    Harris CL
    Semin Immunopathol; 2018 Jan; 40(1):125-140. PubMed ID: 28986638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement in clinical medicine: Clinical trials, case reports and therapy monitoring.
    Ricklin D; Barratt-Due A; Mollnes TE
    Mol Immunol; 2017 Sep; 89():10-21. PubMed ID: 28576323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa.
    Ghias MH; Hyde MJ; Tomalin LE; Morgan BP; Alavi A; Lowes MA; Piguet V
    J Invest Dermatol; 2020 Mar; 140(3):531-536.e1. PubMed ID: 31870626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Can complement blocking arrest peritoneal fibrosis?].
    Esposito V
    G Ital Nefrol; 2010; 27(1):8. PubMed ID: 20191454
    [No Abstract]   [Full Text] [Related]  

  • 17. Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option.
    Qin S; Dong N; Yang M; Wang J; Feng X; Wang Y
    J Immunol Res; 2021; 2021():9945725. PubMed ID: 34368372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation.
    Holers VM; Rohrer B; Tomlinson S
    Adv Exp Med Biol; 2013; 735():137-54. PubMed ID: 23402024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Modulation of the Complement System in Kidney Transplantation: Clinical Indications and Emerging Drug Leads.
    Tatapudi VS; Montgomery RA
    Front Immunol; 2019; 10():2306. PubMed ID: 31632397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Complement Therapeutics in Development as Potential Treatment for Renal Disease.
    Kelleher C; Kocinsky H
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):95-103. PubMed ID: 32553251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.